Marrow adiposity recovery after early zoledronic acid treatment of glucocorticoid-induced bone loss in rabbits assessed by magnetic resonance spectroscopy

Bone

Volumn 52, Issue 2, 2013, Pages 668-675

  Li, Guan Wu ^a   Chang, Shi Xin ^a   Fan, Jing Zheng ^a   Tian, Ya Nan ^a   Xu, Zheng ^b   He, Yan Ming ^a  

^a Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine   (China)

^b XinZhuang Community Health Service Center   (China)

Author keywords

Bone mineral density; Glucocorticoid; Magnetic resonance spectroscopy; Marrow adiposity; Zoledronic acid

Indexed keywords

GLUCOCORTICOID; METHYLPREDNISOLONE; ZOLEDRONIC ACID;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MARROW; CELL DENSITY; CELL SIZE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HEMATOPOIETIC TISSUE; HISTOPATHOLOGY; MARROW ADIPOSITY; MARROW FAT FRACTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSTEOLYSIS; RABBIT; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VERTEBRA;

ABSORPTIOMETRY, PHOTON; ADIPOCYTES; ADIPOSITY; ANIMALS; BODY WEIGHT; BONE DENSITY; BONE MARROW; BONE MARROW CELLS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; FEMUR; GLUCOCORTICOIDS; IMIDAZOLES; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; RABBITS; REPRODUCIBILITY OF RESULTS;

EID: 84871733863     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.11.002     Document Type: Article

References (29)

1. den Uyl D., Bultink I.E., Lems W.F. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 2011, 13:233-240.
2. Compston J. Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis?. Clin Endocrinol (Oxf) 2011, 74:547-550.
3. Majumdar S.R., Lix L.M., Yogendran M., Morin S.N., Metge C.J., Leslie W.D. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008). J Clin Endocrinol Metab 2012, 97:1236-1242.
4. Reid D.M., Devogelaer J.P., Saag K., Roux C., Lau C.S., Reginster J.Y., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-1263.
5. Roux C., Reid D.M., Devogelaer J.P., Saag K., Lau C.S., Reginster J.Y., et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbarspine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int 2012, 23:1083-1090.
6. Li G.W., Tang G.Y., Liu Y., Tang R.B., Peng Y.F., Li W. MR spectroscopy and micro-CT in evaluation of osteoporosis model in rabbits: comparison with histopathology. Eur Radiol 2012, 22:923-929.
7. Casazza K., Hanks L.J., Hidalgo B., Hu H.H., Affuso O. Short-term physical activity intervention decreases femoralbone marrow adipose tissue in young children: a pilot study. Bone 2012, 50:23-27.
8. Wren T.A., Chung S.A., Dorey F.J., Bluml S., Adams G.B., Gilsanz V. Bone marrow fat is inversely related to cortical bone in young and old subjects. J Clin Endocrinol Metab 2011, 96:782-786.
9. Perilli E., Le V., Ma B., Salmon P., Reynolds K., Fazzalari N.L. Detecting early bone changes using in vivo micro-CT in ovariectomized, zoledronic acid-treated, and sham-operated rats. Osteoporos Int 2010, 21:1371-1382.
10. Brouwers J.E., Lambers F.M., Gasser J.A., van Rietbergen B., Huiskes R. Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized Wistar rats assessed by in vivo micro-computed tomography. Calcif Tissue Int 2008, 82:202-211.
11. Castañeda S., Calvo E., Largo R., González-González R., de la Piedra C., Díaz-Curiel M., et al. Characterization of a new experimental model of osteoporosis in rabbits. J Bone Miner Metab 2008, 26:53-59.
12. Carvas J.S., Pereira R.M., Caparbo V.F., Fuller P., Silveira C.A., Lima L.A., et al. A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration. Osteoporos Int 2010, 21:1723-1729.
13. Cohen A., Dempster D.W., Stein E.M., Nickolas T.L., Zhou H., McMahon D.J., et al. Increased marrow adiposity in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 2012, 97:2782-2791.
14. Van Staa T.P., Laan R.F., Barton I.P., Cohen S., Reid D.M., Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224-3229.
15. Feldstein A.C., Elmer P.J., Nichols G.A., Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005, 16:2168-2174.
16. Li G.W., Chang S.X., Xu Z., Chen Y., Bao H., Shi X. Prediction of hip osteoporotic fractures from composite indices of femoral neck strength. Skeletal Radiol 2012, 10.1007/s00256-012-1473-7.
17. Svendsen O.L., Hassager C., Skødt V., Christiansen C. Impact of soft tissue on in vivo accuracy of bone mineral measurements in the spine, hip, and forearm: a human cadaver study. J Bone Miner Res 1995, 10:868-873.
18. Blake G.M., Griffith J.F., Yeung D.K., Leung P.C., Fogelman I. Effect of increasing vertebral marrow fat content on BMD measurement, T-Score status and fracture risk prediction by DXA. Bone 2009, 44:495-501.
19. Griffith J.F., Yeung D.K., Ma H.T., Leung J.C., Kwok T.C., Leung P.C. Bone marrow fat content in the elderly: a reversal of sex difference seen in younger subjects. J Magn Reson Imaging 2012, 36:225-230.
20. Dominguez L.J., Di Bella G., Belvedere M., Barbagallo M. Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology 2011, 12:397-408.
21. Plotkin L.I., Bivi N., Bellido T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 2011, 49:122-127.
22. Brouwers J.E., Ruchelsman M., Rietbergen B., Bouxsein M.L. Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats. Osteoporos Int 2009, 20:1377-1384.
23. Takahashi M., Saha P.K., Wehrli F.W. Skeletal effects of short-term exposure to dexamethasone and response to risedronate treatment studied in vivo in rabbits by magnetic resonance micro-imaging and spectroscopy. J Bone Miner Metab 2006, 24:467-475.
24. Liu L.F., Shen W.J., Zhang Z.H., Wang L.J., Kraemer F.B. Adipocytes decrease Runx2 expression in osteoblastic cells: roles of PPARγ and adiponectin. J Cell Physiol 2010, 225:837-845.
25. Veronesi F., Torricelli P., Borsari V., Tschon M., Rimondini L., Fini M. Mesenchymal stem cells in the aging and osteoporotic population. Crit Rev Eukaryot Gene Expr 2011, 21:363-377.
26. Astudillo P., Ríos S., Pastenes L., Pino A.M., Rodríguez J.P. Increased adipogenesis of osteoporotic human-mesenchymal stem cells (MSCs) characterizes by impaired leptin action. J Cell Biochem 2008, 103:1054-1065.
27. Hardy R., Cooper M.S. Glucocorticoid-induced osteoporosis-a disorder of mesenchymal stromal cells?. Front Endocrinol (Lausanne) 2011, 2:24.
28. Kawai M., de Paula F.J., Rosen C.J. New insights into osteoporosis: the bone-fat connection. J Intern Med 2012, 10.1111/j.1365-2796.2012.02564.x.
29. Duque G., Li W., Adams M., Xu S., Phipps R. Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporos Int 2011, 22:1547-1553.